Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback